

Erratum to: Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan

K. Moriwaki¹ · M. Mouri^{2,3} · H. Hagino⁴

Published online: 21 March 2017

© International Osteoporosis Foundation and National Osteoporosis Foundation 2017

Erratum to: Osteoporos Int

DOI 10.1007/s00198-017-3973-8

In Table 2, the incorrect value of 66.00 was given for the category 70 years old, T-score -3.0 / BT (vs ZOL + BT) in the column showing 10-year probability (%) of hip fracture. The correct value is 6.00, as shown here in the corrected version of the table.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00198-017-3973-8>

✉ H. Hagino
hagino@med.tottori-u.ac.jp

¹ Department of Medical Statistics, Kobe Pharmaceutical University, 4-19-1, Motoyamakita, Higashinada, Kobe 658-8558, Japan

² Global Health Research Coordinating Center, Kanagawa Academy of Science and Technology, KSP East 3F 309, 3-2-1, Sakado, Takatsu, Kawasaki, Kanagawa, Japan

³ Project Research Institutes, Comprehensive Research Organization, Waseda University, Tokyo 169-8050, Japan

⁴ School of Health Sciences, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan

Table 2 Results of scenario analysis on treatment persistence

| | 10-year fracture probability (%) | | | RR of hip fracture | RR of major fracture | QALYs | Incremental QALYs | Cost (USD) | Incremental cost (USD) | ICER (USD per QALY) | INMB (USD) | |
|-----------------------------|----------------------------------|--------------------|----------------|--------------------|----------------------|--------|-------------------|------------|------------------------|---------------------|------------|--|
| | Hip fracture | Vertebral fracture | Other fracture | | | | | | | | | |
| 70 years old, T-score - 2.0 | | | | | | | | | | | | |
| BT | 2.20 | 9.20 | 6.20 | - | - | 11.331 | - | 17,530 | - | - | - | |
| ALN + BT (vs BT) | 2.00 | 8.30 | 5.90 | 0.909 | 0.920 | 11.346 | 0.015 | 17,830 | 300 | 19,904 | 453 | |
| ZOL + BT (vs ALN + BT) | 1.90 | 7.30 | 5.50 | 0.950 | 0.907 | 11.356 | 0.010 | 18,326 | 497 | 47,435 | 27 | |
| 65 years old, T-score - 2.5 | | | | | | | | | | | | |
| BT | 2.50 | 9.50 | 7.00 | - | - | 13.472 | - | 23,988 | - | - | - | |
| ALN + BT (vs BT) | 2.30 | 8.60 | 6.60 | 0.920 | 0.921 | 13.503 | 0.031 | 24,029 | 41 | 1322 | 1499 | |
| ZOL + BT (vs ALN + BT) | 2.20 | 7.60 | 6.20 | 0.957 | 0.914 | 13.520 | 0.017 | 24,447 | 418 | 25,067 | 416 | |
| 70 years old, T-score - 2.5 | | | | | | | | | | | | |
| BT | 3.60 | 12.00 | 7.30 | - | - | 11.167 | - | 20,364 | - | - | - | |
| ALN + BT (vs BT) | 3.30 | 10.80 | 6.90 | 0.917 | 0.917 | 11.193 | 0.026 | 20,460 | 95 | 3620 | 1222 | |
| ZOL + BT (vs ALN + BT) | 3.10 | 9.50 | 6.40 | 0.939 | 0.905 | 11.209 | 0.015 | 20,868 | 408 | 27,018 | 347 | |
| 75 years old, T-score - 2.5 | | | | | | | | | | | | |
| BT | 5.20 | 14.80 | 7.30 | - | - | 8.905 | - | 16,755 | - | - | - | |
| ALN + BT (vs BT) | 4.60 | 13.30 | 6.80 | 0.885 | 0.905 | 8.934 | 0.029 | 16,885 | 130 | 4523 | 1309 | |
| ZOL + BT (vs ALN + BT) | 4.40 | 11.60 | 6.30 | 0.957 | 0.903 | 8.948 | 0.014 | 17,252 | 367 | 25,747 | 346 | |
| 70 years old, T-score - 3.0 | | | | | | | | | | | | |
| ALN + BT | 5.30 | 14.10 | 8.10 | - | - | 10.979 | - | 24,209 | - | - | - | |
| ZOL + BT (vs ALN + BT) | 5.00 | 12.40 | 7.50 | 0.943 | 0.905 | 11.000 | 0.022 | 24,443 | 235 | 10,749 | 857 | |
| BT (vs ZOL + BT) | 6.00 | 15.70 | 8.60 | 1.200 | 1.217 | 10.935 | -0.065 | 24,534 | 91 | Dominated | -3341 | |

BT: basic treatment (placebo + calcium + vitamin D), ZOL: once-yearly injection of zoledronic acid 5 mg, ALN: once-weekly oral alendronate 35 mg. 1 USD = 120 JPY (February 2016 exchange rate). All strategies were ranked according to costs

RR relative risk, QALYs quality-adjusted life years, ICER incremental cost-effectiveness ratio, INMB incremental net monetary benefit